Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS, Samsung Bio Ink 10-Year Mfg. Pact | Contract Pharma
Breaking News, Collaborations & Alliances

BMS, Samsung Bio Ink 10-Year Mfg. Pact

Cancer drug to be made in Songdo Incheon

Bristol-Myers Squibb and Samsung BioLogics have entered into a 10-year agreement under which Samsung will manufacture a commercial antibody cancer drug for BMS at its recently completed plant in Songdo Incheon, South Korea.

Financial terms were not disclosed. Technology transfer and trial production will commence in July 2013 and commercial production will immediately begin following regulatory approvals.

“We are pleased to announce this strategic manufacturing relationship with Bristol-Myers Squibb and look forward to delivering best-in-class manufacturing services with the highest global quality standards,” said Tae-Han Kim, president and chief executive officer of Samsung BioLogics. “The relationship with Bristol-Myers Squibb represents the validation of our long-term commitment to the biopharmaceutical manufacturing industry.”

“Our agreement with Samsung is an important part of our company’s overall manufacturing and supply strategy focused on creating long-term relationships with high quality manufacturing partners around the world,” said Louis Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb. “This agreement increases our biologic manufacturing capacity to help ensure sufficient long-term supply of our commercial products.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters